~Hepatitis C, Part 10 - References

REFERENCES, continued

300. Aoki K, Nakajima A et al. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol. 2003;85(2-5):469-72.
301. Araneo BA, Shelby J et al. Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence. Arch Surg. 1993;128(3):318-25.
302. Loria RM, Inge TH et al. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol. 1988;26(3):301-14.
303. Casson PR, Carson SA. Androgen replacement therapy in women: myths and realities. Int J Fertil Menopausal Stud. 1996;41(4):412-22.
304. Nestler JE, Kahwash Z. Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. J Clin Invest. 1994;94(4):1484-9.
305. Nestler JE, Beer NA et al. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab. 1994;78(3):549-54.
306. Nestler JE, Beer NA et al. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab. 1995;80(2):700-6.
307. Tagliaferro AR, Roebuck BD et al. Enhancement of pancreatic carcinogenesis by dehydroepiandrosterone. Adv Exp Med Biol. 1992;322:119-29.
308. Ashraf-Khorassani M, Taylor LT. Sequential fractionation of grape seeds into oils, polyphenols, and procyanidins via a single system employing CO2-based fluids. J Agric Food Chem. 2004;52(9):2440-4.
309. Bagchi D, Garg A et al. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Res Commun Mol Pathol Pharmacol. 1997;95(2):179-89.
310. Peng Q, Wei Z et al. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci. 2000;57(5):834-41.
311. Bagchi D, Garg A et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol. 1998;30(5):771-6.
312. Cheshier JE, Ardestani-Kaboudanian S et al. Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Life Sci. 1996;58(5):87-96.
313. Blazso G, Gabor M. Oedema-inhibiting effect of procyanidin. Acta Physiol Acad Sci Hung. 1980;56(2):235-40.
314. Ray SD, Kumar MA et al. A novel proanthocyanidin IH636 grape seed extract increases in vivo Bcl-XL expression and prevents acetaminophen-induced programmed and unprogrammed cell death in mouse liver. Arch Biochem Biophys. 1999;369(1):42-58.
315. ABC (American Botanical Council). Proanthocyanidins. Austin, TX: American Botanical Council. Available at: http://www.herbalgram.org. Accessed August 13, 2004.
316. Flora K, Hahn M et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93(2):139-43.
317. Feher J, Lang I et al. In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med. 1990;15(2-3):129-34.
318. Basaga H, Poli G et al. Free radical scavenging and antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Cell Biochem Funct. 1997;15(1):27-33.
319. Muriel P, Garciapina T et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol. 1992;12(6):439-42.
320. Davila JC, Lenherr A et al. Protective effect of flavonoids on drug-induced hepatotoxicity in vitro. Toxicology. 1989;57(3):267-86.
321. Shear NH, Malkiewicz IM et al. Acetaminophen-induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Skin Pharmacol. 1995;8(6):279-91.
322. Sonnenbichler J, Mattersberger J et al. [Mechanism of silybin action, III. Resorption of the flavonolignane derivative silybin into rat liver cells (author's transl)]. Hoppe Seylers Z Physiol Chem. 1980;361(11):1751-6.
323. Garrido A, Arancibia C et al. Acetaminophen does not induce oxidative stress in isolated rat hepatocytes: its probable antioxidant effect is potentiated by the flavonoid silybin. Pharmacol Toxicol. 1991;69(1):9-12.
324. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15(7):465-89.
325. Boari C, Montanari FM et al. [Toxic occupational liver diseases. Therapeutic effects of silymarin]. Minerva Med. 1981;72(40):2679-88.
326. Ferenci P, Dragosics B et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105-13.
327. Feher J, Deak G et al. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. Orv Hetil. 1989;130(51):2723-7.
328. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982;17(4):517-21.
329. Bunout D, Hirsch S et al. [Controlled study of the effect of silymarin on alcoholic liver disease]. Rev Med Chil. 1992;120(12):1370-5.
330. Trinchet JC, Coste T et al. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients]. Gastroenterol Clin Biol. 1989;13(2):120-4.
331. Bode JC, Schmidt U et al. [Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author's transl)]. Med Klin. 1977;72(12):513-8.
332. Magliulo E, Gagliardi B et al. [Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl)]. Med Klin. 1978;73(28-29):1060-5.
333. Buzzelli G, Moscarella S et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993;31(9):456-60.
334. Kiesewetter E, Leodolter I et al. [Results of two double-blind studies on the effect of silymarine in chronic hepatitis (author's transl)]. Leber Magen Darm. 1977;7(5):318-23.
335. Bhatia N, Zhao J et al. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett. 1999;147(1-2):77-84.
336. Katiyar SK, Korman NJ et al. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst. 1997;89(8):556-66.
337. LegalonŽ-PI. Madaus Educational Monograph, Koln, West Germany; 1994.
338. Bean P. The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab. 2002;21(4):19-21.
339. Abe M, Akbar F et al. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol. 2003;38(10):962-7.
340. Xu Q, Lu J et al. Liver injury model induced in mice by a cellular immunologic mechanism--study for use in immunopharmacological evaluations. Pharmacol Res. 1997;35(4):273-8.
341. Gallo D, Giacomelli S et al. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer. 2003;39(16):2403-10.
342. Chlopcikova S, Psotova J et al. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res. 2004;18(2):107-10.
343. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi. 2000;120(10):849-62.
344. Kroes BH, Beukelman CJ et al. Inhibition of human complement by beta-glycyrrhetinic acid. Immunology. 1997;90(1):115-20.
345. Crance JM, Leveque F et al. Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994;23(1):63-76.
346. Takahara T, Watanabe A et al. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol. 1994;21(4):601-9.
347. Numazaki K, Umetsu M et al. Effect of glycyrrhizin in children with liver dysfunction associated with cytomegalovirus infection. Tohoku J Exp Med. 1994;172(2):147-53.
348. Arase Y, Ikeda K et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79(8):1494-500.
349. Utsunomiya T, Kobayashi M et al. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother. 1997;41(3):551-6.
350. van Rossum TG, Vulto AG et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96(8):2432-7.
351. Yamamura Y, Kotaki H et al. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Biopharm Drug Dispos. 1997;18(8):717-25.
352. Abe Y, Ueda T et al. [Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C]. Nippon Rinsho. 1994;52(7):1817-22.
353. van Rossum TG, Vulto AG et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol. 1999;14(11):1093-9.
354. Tsubota A, Kumada H et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11(10):1077-83.
355. Kageyama Y. A case of pseudoaldosteronism induced by glycyrrhizin. Nippon Jinzo Gakkai Shi. 1992;34(1):99-102.
356. Duke J. Handbook of Medicinal Herbs. ed. Anonymous. Boca Raton, FL: CRC Press;1985.
357. Hasegawa N, Niimi N et al. Vitamin C is one of the lipolytic substances in green tea. Phytother Res. 2002;16(Suppl 1):91-2.
358. Brown MD. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern Med Rev. 1999;4(5):360-70.
359. Chen A, Zhang L et al. The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression. Biochem J. 2002;368(Pt 3):695-704.
360. Stoner GD, Mukhtar H. Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl. 1995;22:169-80.
361. Kohlmeier L, Weterings KG et al. Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer. 1997;27(1):1-13.
362. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer. 1998;31(3):151-9.
363. Lin AM, Chyi BY et al. The antioxidative property of green tea against iron-induced oxidative stress in rat brain. Chin J Physiol. 1998;41(4):189-94.
364. Hasegawa R, Takekida K et al. [Inhibitory effect of green tea infusion of hepatotoxicity]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 1998;(116):82-91.
365. Sadakata SF. Mortality among female practitioners of Chanoyu (Japanese "tea-ceremony"). Tohoku J Exp Med. 1992;166:475-7.
366. Zhong Z, Froh M et al. Polyphenols from Camellia sinenesis attenuate experimental cholestasis-induced liver fibrosis in rats. Am J Physiol Gastrointest Liver Physiol. 2003;285(5):1004-13.
367. Jimenez-Lopez JM, Cederbaum AI. Green tea polyphenol epigallocatechin-3-gallate protects HepG2 cells against CYP2E1-dependent toxicity. Free Radic Biol Med. 2004;36(3):359-70.
368. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. 1999;33(4):426-8.
369. He P, Noda Y et al. Suppressive effect of coffee on lipopolysaccharide-induced hepatitis in D-galactosamine-sensitized rats. Biosci Biotechnol Biochem. 2001;65(8):1924-7.
370. Matthes H. Hepatitis C may respond to green tomatoes and mistletoe extracts when interferon fails.2004.
371. Kim Y, DiSilvestro R et al. Effects of lycopene-beadlet or tomato-powder feeding on carbon tetrachloride-induced hepatotoxicty in rats. Phytomedicine. 2004;11(2-3):152-6.
372. Morisco F, Vitaglione P et al. Tomato-based functional food as interferon adjuvant in HCV eradication therapy. J Clin Gastroenterol. 2004;38(6 Suppl):118-20.
373. Dietitians of Canada. Hepatitis C: nutrition care Canadian guidelines for health care providers. Can J Diet Pract Res. 2003;64(3):139-41.
374. Riley TR3, Bhatti AM. Preventive strategies in chronic liver disease: Part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise. Am Fam Physician. 2001;64(9):1555-60.
375. Arico S, Corrao G et al. Alcoholic liver cirrhosis after the advent of hepatitis C virus: some reflections on its epidemiology and on the concept of attributable risk. Collaborative GESIA and AISF Groups. Gruppo Epidemiologico della Societa Italiana di Alcologia and Associazione Italiana per lo Studio del Fegato. Ital J Gastroenterol Hepatol. 1997;29(1):75-80.
376. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1):71-9.
377. Iwasa M, Iwata K et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition. 2004;20(4):368-71.
378. Gottrand F, Michaud L et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr. 1996;155(12):1031-4.
379. Okumura A. Nutrition is more important than th1-dominated condition for better response in interferon alpha-2b/ribavirin therapy. Abstract 323 (poster). American Association for the Study of Liver Diseases, 54th Annual Meeting, Boston, MA, 2003. Hepatology 38:4 (Suppl).


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.